Cingulate Inc (CING) Stock Price, Quote & News

Company Profile

Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials. It also develops CTx-2103 (buspirone) that is in a formulation stage for the treatment of anxiety and mental health disorders; and plans to initiate the clinical plan for CTx-1...

Industry: Biotechnology

Sector: Healthcare

Phone: 913 942 2300

Website: www.cingulate.com

Address:

1901 West 47th Place, Kansas City, United States

Sam898989 Sep. 11 at 12:59 AM

$CING The Wednesday Weekly USA patent update. Change or no change, every Wednesday, will be positing it: Here’s the updated status for Application US 18/661,378 (Tripulse Release Stimulant Formulations), as of September 10, 2025: ________________________________________ Application US18/661,378 (Tripulse Release Stimulant Formulations) • 2024-05-10 – Application filed by Cingulate Therapeutics LLC • 2024-05-10 – Priority date established (same day as filing) • 2024-11-11 – Assignment recorded to Cingulate Therapeutics LLC (Reel/Frame 069201/0426) Google Patents • 2025-02-13 – Publication of application as US 2025/0049722 A1 Google Patents • 2025-09-10 (today) – Status: Pending (no Office Action issued yet; still early in prosecution) My best guess is Office action starts Q4 of 2025. We are almost there IMO.

0 · Reply

smoketuna Sep. 10 at 7:07 PM

$CING 82% with 🎯 TunaSignal.ai score! while price $3.86 - Catch the Big Movers Before They Break Out - Powered by AI

0 · Reply

JacobJones1 Sep. 9 at 3:07 PM

$CING if their ADHD drug is approved (it should), this will spike hard!!!

1 · Reply

sam9420 Sep. 9 at 9:48 AM

$CING what the expected price for cing in September ,?!

1 · Reply

Jojo_Mojo12 Sep. 9 at 3:53 AM

$CING

0 · Reply

sam9420 Sep. 8 at 5:52 PM

$CING NDA acceptance will be sudden in any time from now. It will be great 👌

1 · Reply

Mazinga_Mong Sep. 8 at 3:57 PM

$CING

0 · Reply

BullFunds Sep. 4 at 6:17 PM

$CING they haven’t done yet

1 · Reply

gon432 Sep. 4 at 4:11 PM

$CING money making

1 · Reply

RunnerSignals Sep. 4 at 12:52 PM

Support watch $CING $KDP $HRL $CSIQ $ZS all testing key levels will buyers step up or do we see breakdowns? Timing the bounce is everything

0 · Reply

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 2Q25

Aug 19, 2025, 8:45 AM EDT - 23 days ago

Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights

Aug 15, 2025, 9:00 AM EDT - 27 days ago

Cingulate Provides Management Team Update

Aug 6, 2025, 8:45 AM EDT - 5 weeks ago

Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301

Jun 18, 2025, 8:00 AM EDT - 3 months ago

Stonegate Capital Partners Initiates Coverage on Cingulate Inc. (CING)

May 8, 2025, 4:30 PM EDT - 4 months ago

Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets

Apr 9, 2025, 8:00 AM EDT - 5 months ago

Cingulate Receives $3 Million Grant from Private Foundation to Accelerate Development of Anxiety Asset CTx-2103 (buspirone)

Mar 26, 2025, 5:00 PM EDT - 6 months ago

Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved

Dec 23, 2024, 7:30 AM EST - 9 months ago

Cingulate Completes Financing Transaction for Net Proceeds of $5,000,000

Nov 7, 2024, 7:30 AM EST - 11 months ago

Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market

Oct 8, 2024, 3:15 PM EDT - 1 year ago

Cingulate's Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show

Sep 12, 2024, 8:30 AM EDT - 1 year ago

Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301

Aug 27, 2024, 4:30 PM EDT - 1 year ago

Cingulate to Participate in Benzinga All Live Access Event

Aug 23, 2024, 4:45 PM EDT - 1 year ago

Cingulate Announces Adjournment of Special Meeting

Aug 16, 2024, 12:36 PM EDT - 1 year ago

Cingulate stock surges 115% after European patent approval for ADHD treatment: Is it a buy?

Aug 15, 2024, 7:45 AM EDT - 1 year ago

Cingulate Issued European Patent for Lead Asset CTx-1301 for the Treatment of ADHD

Aug 13, 2024, 7:45 AM EDT - 1 year ago

Cingulate Reports Second Quarter 2024 Financial Results and Provides Development Update on Major Milestones Achieved

Jun 28, 2024, 9:15 AM EDT - 1 year ago

Cingulate Announces Exercise of Warrants for $1.86 Million Gross Proceeds

Jun 25, 2024, 4:30 PM EDT - 1 year ago

Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access Event

Jun 25, 2024, 9:20 AM EDT - 1 year ago

Cingulate Achieves Key Manufacturing Milestone in the Development of its ADHD Drug CTx-1301 in Preparation for FDA Marketing Clearance

May 8, 2024, 7:00 AM EDT - 1 year ago

Cingulate Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update

Apr 30, 2024, 5:45 AM EDT - 1 year ago

Peter J. Werth, Successful Pharma Entrepreneur, Philanthropist, Cingulate Investor and Board Member, to be Featured with Chairman and CEO Shane J. Schaffer on Benzinga All Live Access

Apr 16, 2024, 5:00 PM EDT - 1 year ago

Cingulate to Participate in Planet MicroCap Showcase: Vegas 2024

Apr 1, 2024, 8:00 AM EDT - 1 year ago

Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update

Mar 6, 2024, 6:45 AM EST - 1 year ago

Cingulate to Attend DCAT Week 2024 in New York City

Feb 13, 2024, 6:45 AM EST - 1 year ago

Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors

Feb 6, 2024, 4:15 PM EST - 1 year ago

Cingulate Announces Closing of $7.5 Million Public Offering

Feb 2, 2024, 9:15 AM EST - 1 year ago

Cingulate Announces Pricing of $7.5 Million Public Offering

Jan 29, 2024, 8:00 AM EST - 1 year ago

Longtime Cingulate Controller Jennifer Callahan Promoted to CFO

Jan 29, 2024, 6:45 AM EST - 1 year ago

Werth Family Investment Associates Converts Remaining $3.3M of Debt and Accrued Interest into Cingulate Equity at Premium to Market

Dec 28, 2023, 7:19 AM EST - 1 year ago

Cingulate's stock skyrockets again, as ADHD treatment developer as delisting is delayed pending a February hearing

Dec 1, 2023, 9:00 AM EST - 1 year ago

Cingulate Receives Guidance from FDA on Path Forward for Anxiety Asset CTx-2103 (buspirone)

Nov 13, 2023, 4:15 PM EST - 1 year ago

Cingulate Inc. Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update

Oct 17, 2023, 2:22 PM EDT - 2 years ago

Cingulate to Host CNS Key Opinion Leader Panel in New York City

Sep 21, 2023, 1:30 PM EDT - 2 years ago

Cingulate Inc. to Present at the LD Micro Main Event XVI

Sep 21, 2023, 11:23 AM EDT - 2 years ago

Cingulate Inc. To Present at the LD Micro Main Event XVI

Sep 13, 2023, 4:15 PM EDT - 2 years ago

Cingulate Announces Closing of $4.0 Million Public Offering

Sep 11, 2023, 9:22 AM EDT - 2 years ago

Cingulate Announces Pricing of $4.0 Million Public Offering

Sep 11, 2023, 6:00 AM EDT - 2 years ago

Cingulate Announces Detailed Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD

Sep 8, 2023, 4:31 PM EDT - 2 years ago

Werth Family Investment Associates Converts $5.8 Million of Debt into Cingulate Equity at a Premium

Sep 6, 2023, 9:00 AM EDT - 2 years ago

Dr. Vince Clinical Research Announces First Dosing in Cingulate Therapeutics' CTx-1301 Phase III Laboratory Classroom Study in ADHD Patients

Sep 5, 2023, 8:00 AM EDT - 2 years ago

Cingulate Announces Presentation of Full Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD at Psych Congress 2023

Aug 14, 2023, 4:15 PM EDT - 2 years ago

Cingulate Inc. Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update

Jun 29, 2023, 8:00 AM EDT - 2 years ago

Cingulate Successfully Manufactures Clinical Supply – Initiation of Pediatric Phase 3 Studies to Commence in July and August

Jun 14, 2023, 3:45 PM EDT - 2 years ago

Cingulate to Participate in the Healthcare Virtual Conference Part II Presented by Maxim Group and Hosted by M-Vest

Jun 8, 2023, 7:00 AM EDT - 2 years ago

Cingulate Completes Phase 3 Adult Trial of CTx-1301 (dexmethylphenidate) for ADHD

May 25, 2023, 3:55 PM EDT - 2 years ago

Cingulate to Present at 13th Annual LD Micro Invitational

May 12, 2023, 3:45 PM EDT - 2 years ago

Cingulate, Indegene to Participate in Benzinga All Live Access Event

May 10, 2023, 4:15 PM EDT - 2 years ago

Cingulate Inc. Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update

May 3, 2023, 6:45 AM EDT - 2 years ago

Cingulate Announces Successful Transfer of CTx-1301 (dexmethylphenidate) Proprietary PTR™ Manufacturing Processes to Societal CDMO

Sam898989 Sep. 11 at 12:59 AM

0 · Reply

smoketuna Sep. 10 at 7:07 PM

$CING 82% with 🎯 TunaSignal.ai score! while price $3.86 - Catch the Big Movers Before They Break Out - Powered by AI

0 · Reply

JacobJones1 Sep. 9 at 3:07 PM

$CING if their ADHD drug is approved (it should), this will spike hard!!!

1 · Reply

sam9420 Sep. 9 at 9:48 AM

$CING what the expected price for cing in September ,?!

1 · Reply

Jojo_Mojo12 Sep. 9 at 3:53 AM

$CING

0 · Reply

sam9420 Sep. 8 at 5:52 PM

$CING NDA acceptance will be sudden in any time from now. It will be great 👌

1 · Reply

Mazinga_Mong Sep. 8 at 3:57 PM

$CING

0 · Reply

BullFunds Sep. 4 at 6:17 PM

$CING they haven’t done yet

1 · Reply

gon432 Sep. 4 at 4:11 PM

$CING money making

1 · Reply

RunnerSignals Sep. 4 at 12:52 PM

Support watch $CING $KDP $HRL $CSIQ $ZS all testing key levels will buyers step up or do we see breakdowns? Timing the bounce is everything

0 · Reply

Sam898989 Sep. 4 at 12:07 AM

$CING I also received my Proxy vote in the mail today. Voting items: 1. To approve, for the purposes of complying with Nasdaq listing the issuance of more than 20% of the issued and outstanding common stock pursuant to purchase agreement with Lincoln Park Capital Fund. 2. To approve the adjournment of the special meeting to a later date or dates in the even there are insufficient votes for the approval of the issuance proposal. Special meeting is September 25, 2025 @ 10am CDT.

0 · Reply

Sam898989 Sep. 4 at 12:00 AM

$CING The Wednesday Weekly USA patent update. Change or no change, every Wednesday, will be positing it: Here’s the updated status for Application US 18/661,378 (Tripulse Release Stimulant Formulations), as of September 3, 2025: ---------------------------------------------------- Application US18/661,378 (Tripulse Release Stimulant Formulations) • 2024-05-10 – Application filed by Cingulate Therapeutics LLC • 2024-05-10 – Priority date established (same day as filing) • 2024-11-11 – Assignment recorded to Cingulate Therapeutics LLC (Reel/Frame 069201/0426) • 2025-02-13 – Publication of application as US 2025/0049722 A1 • 2025-09-03 (today) – Status: Pending (no Office Action issued yet; still in early prosecution phase)

1 · Reply

sam9420 Sep. 3 at 12:35 PM

$CING will return above 4$ today,it is still chance at these prices

1 · Reply

BullFunds Sep. 3 at 5:07 AM

$CING

4 · Reply

sam9420 Sep. 2 at 12:58 PM

$CING let's go to have a big month ⏳ Step by step to 8$ at September

0 · Reply

sam9420 Aug. 31 at 11:12 AM

$CING tic tac to 8$ in September

0 · Reply

ibaian Aug. 30 at 3:10 PM

$CING SHOULD BE $ 20 SOON

1 · Reply

Sharkboy101 Aug. 29 at 4:14 PM

$CING I have ADHD so this is a self investment

0 · Reply

sam9420 Aug. 29 at 2:10 PM

$CING from next week at Tuesday,it will be just 30days or less to NDA acceptance. Cing too cheap price from now

1 · Reply

Sam898989 Aug. 29 at 4:21 AM

$CING Key News & Filings from August 28, 2025 1. SEC Form 8-K Filing – Executive Changes & Separation Agreement On August 28, 2025, Cingulate filed an 8-K reporting several corporate governance updates: John A. Roberts has been appointed Executive Chairman effective August 14. He will receive a cash retainer of $10,000/month for this role. CEO Shane Schaffer has been placed on administrative leave, with his salary reduced to 75% while he remains eligible for benefits. Laurie Myers, whose employment ended on August 7, signed a Separation Agreement with Cingulate Therapeutics LLC on August 28. The agreement includes confidentiality, non-competition, and non-solicitation clauses; she will receive $436,720 in separation pay over 12 months, vesting of unvested stock options, and must comply with post-employment restrictions.

1 · Reply

gon432 Aug. 28 at 6:39 PM

$CING all in

1 · Reply

sam9420 Aug. 28 at 2:16 PM

$CING chance to add more

0 · Reply

Market Cap	20.89M
Revenue (ttm)	0.00
Net Income (ttm)	-15.55M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	140,793
Avg Vol	135,518
Day's Range	N/A - N/A
Shares Out	5.41M
Stochastic %K	38%
Beta	-0.76
Analysts	Strong Sell
Price Target	$29.00